2024
Tumor response assessment in hepatocellular carcinoma treated with immunotherapy: imaging biomarkers for clinical decision-making
Sobirey R, Matuschewski N, Gross M, Lin M, Kao T, Kasolowsky V, Strazzabosco M, Stein S, Savic L, Gebauer B, Jaffe A, Duncan J, Madoff D, Chapiro J. Tumor response assessment in hepatocellular carcinoma treated with immunotherapy: imaging biomarkers for clinical decision-making. European Radiology 2024, 1-11. PMID: 39033181, DOI: 10.1007/s00330-024-10955-6.Peer-Reviewed Original ResearchMedian overall survivalTumor response criteriaTumor response assessmentHepatocellular carcinoma patientsHepatocellular carcinomaTumor responseOverall survivalResponse criteriaResponse assessmentNon-respondersPoorer median overall survivalPrediction of tumor responsePredictive valueHepatocellular carcinoma immunotherapyDisease controlPrognostic of survivalClinical baseline parametersLog-rank testKaplan-Meier curvesMultivariate Cox regressionPredicting overall survivalCox regression modelsSurvival benefitStratify patientsMRI pre-Outcomes of repeat conventional transarterial chemoembolization in patients with liver metastases
Ghabili K, Windham-Herman A, Konstantinidis M, Murali N, Borde T, Adam L, Laage-Gaupp F, Lin M, Chapiro J, Georgiades C, Nezami N. Outcomes of repeat conventional transarterial chemoembolization in patients with liver metastases. Annals Of Hepatology 2024, 29: 101529. PMID: 39033928, PMCID: PMC11558520, DOI: 10.1016/j.aohep.2024.101529.Peer-Reviewed Original ResearchConventional transarterial chemoembolizationLiver metastasesNeuroendocrine tumorsColorectal carcinomaTransarterial chemoembolizationOverall survivalLung cancerAssociated with improved patient survivalManagement of liver metastasesMetastatic liver lesionsSingle-institution analysisNonresponding patientsSurvival outcomesPatient survivalResponse assessmentTarget lesionsMetastasisLiver lesionsPatientsResponse rateChemoembolizationSurvivalLiverLesionsCancerAutomated graded prognostic assessment for patients with hepatocellular carcinoma using machine learning
Gross M, Haider S, Ze’evi T, Huber S, Arora S, Kucukkaya A, Iseke S, Gebauer B, Fleckenstein F, Dewey M, Jaffe A, Strazzabosco M, Chapiro J, Onofrey J. Automated graded prognostic assessment for patients with hepatocellular carcinoma using machine learning. European Radiology 2024, 34: 6940-6952. PMID: 38536464, PMCID: PMC11399284, DOI: 10.1007/s00330-024-10624-8.Peer-Reviewed Original ResearchContrast-enhanced magnetic resonance imagingMagnetic resonance imagingClinical staging systemTime of diagnosisHepatocellular carcinomaClinical dataMortality risk predictionOverall survivalStaging systemRadiomic featuresManagement of hepatocellular carcinomaPersonalized follow-up strategiesAssociated with OSMethodsThis retrospective studyHepatocellular carcinoma patientsBaseline magnetic resonance imagingMRI radiomics featuresIndependent validation cohortHarrell's C-indexRisk predictionFollow-up strategiesHigh-risk groupPredictive risk scoreRadiomics feature extractionMedian timeHigh‐resolution extracellular pH imaging of liver cancer with multiparametric MR using Deep Image Prior
Dong S, Shewarega A, Chapiro J, Cai Z, Hyder F, Coman D, Duncan J. High‐resolution extracellular pH imaging of liver cancer with multiparametric MR using Deep Image Prior. NMR In Biomedicine 2024, 37: e5145. PMID: 38488205, DOI: 10.1002/nbm.5145.Peer-Reviewed Original ResearchDeep Image PriorU-NetUnsupervised deep learning techniquesU-Net parametersDeep learning techniquesHigh-resolution ground truthU-Net architectureSuper-resolution imagingImage priorsSuper-resolutionGround truthMean absolute errorDeepSpatial resolutionPostprocessing methodDeep imagingAbsolute errorImagesAnatomical MR imagesMR spectroscopic imagingAnatomical informationSpectroscopic imagingInformationAcquisition timeErrorEffect of Incomplete Cryoablation and Matrix Metalloproteinase Inhibition on Intratumoral CD8+ T-Cell Infiltration in Murine Hepatocellular Carcinoma.
Shewarega A, Santana J, Nam D, Berz A, Tefera J, Kahl V, Mishra S, Coman D, Duncan J, Roberts S, Wetter A, Madoff D, Chapiro J. Effect of Incomplete Cryoablation and Matrix Metalloproteinase Inhibition on Intratumoral CD8+ T-Cell Infiltration in Murine Hepatocellular Carcinoma. Radiology 2024, 310: e232365. PMID: 38349244, PMCID: PMC10902598, DOI: 10.1148/radiol.232365.Peer-Reviewed Original ResearchConceptsT cell infiltrationCD8<sup>+</sup> T cellsMatrix metalloproteinase inhibitionT cellsHepatocellular carcinomaMatrix metalloproteinase inhibitorsMatrix metalloproteinasesResidual tumorCXCR3<sup>+</sup> CD8<sup>+</sup> T cellsCytotoxic CD8<sup>+</sup> T cell infiltrationIntratumoral CD8+ T cell infiltrationCD8+ T cell infiltrationCD8<sup>+</sup> T cell infiltrationMouse model of hepatocellular carcinomaEarly-stage hepatocellular carcinomaImage-guided tumor ablationUnpaired Student's <i>t</i> testModel of hepatocellular carcinomaFirst-line therapyMurine hepatocellular carcinomaT cell subsetsTumor-associated macrophagesMurine HCC modelLocal immune responseFemale BALB/c miceAtezolizumab and bevacizumab in combination with TACE for patients with BCLC B HCC.
Stein S, Cheng W, Wiess C, Pollak J, Perez Lozada J, Chapiro J, Madoff D. Atezolizumab and bevacizumab in combination with TACE for patients with BCLC B HCC. Journal Of Clinical Oncology 2024, 42: tps584-tps584. DOI: 10.1200/jco.2024.42.3_suppl.tps584.Peer-Reviewed Original ResearchRates of grade 3Grade 3Child-Pugh A cirrhosisBCLC-B HCCCombination of atezolizumabCurative intent therapyMain portal veinRisk of bleedingDiagnosis of HCCSignificant autoimmune diseaseSingle arm pilot studyB HCCECOG PSEffective regimenOpen-labelOverall survivalGastroesophageal varicesIntent therapyPredicted probabilityAutoimmune diseasesHepatic arteryPortal veinHepatic encephalopathyPatientsImprove outcomesAutomated MRI liver segmentation for anatomical segmentation, liver volumetry, and the extraction of radiomics
Gross M, Huber S, Arora S, Ze’evi T, Haider S, Kucukkaya A, Iseke S, Kuhn T, Gebauer B, Michallek F, Dewey M, Vilgrain V, Sartoris R, Ronot M, Jaffe A, Strazzabosco M, Chapiro J, Onofrey J. Automated MRI liver segmentation for anatomical segmentation, liver volumetry, and the extraction of radiomics. European Radiology 2024, 34: 5056-5065. PMID: 38217704, PMCID: PMC11245591, DOI: 10.1007/s00330-023-10495-5.Peer-Reviewed Original ResearchMagnetic resonance imagingRadiomics feature extractionLiver volumetryIntraclass correlation coefficientRadiomic featuresLiver segmentationAutomated liver volumetryHepatocellular carcinoma patientsMann-Whitney U testAutomated liver segmentationManual segmentationQuantitative imaging biomarkersCarcinoma patientsRetrospective studyInstitutional databaseAnatomical localizationClinical relevanceManual volumetryMann-WhitneyU testExternal validationInternal test setImaging biomarkersInclusion criteriaResultsIn total
2023
Correction to: Consensus report from the 10th Global Forum for Liver Magnetic Resonance Imaging: developments in HCC management
Taouli B, Ba-Ssalamah A, Chapiro J, Chhatwal J, Fowler K, Kang T, Knobloch G, Koh D, Kudo M, Lee J, Murakami T, Pinato D, Ringe K, Song B, Tabrizian P, Wang J, Yoon J, Zeng M, Zhou J, Vilgrain V. Correction to: Consensus report from the 10th Global Forum for Liver Magnetic Resonance Imaging: developments in HCC management. European Radiology 2023, 34: 4845-4846. PMID: 38112766, PMCID: PMC11213717, DOI: 10.1007/s00330-023-10484-8.Peer-Reviewed Original ResearchEthiodized oil as an imaging biomarker after conventional transarterial chemoembolization
Mendiratta-Lala M, Aslam A, Bai H, Chapiro J, De Baere T, Miyayama S, Chernyak V, Matsui O, Vilgrain V, Fidelman N. Ethiodized oil as an imaging biomarker after conventional transarterial chemoembolization. European Radiology 2023, 34: 3284-3297. PMID: 37930412, PMCID: PMC11126446, DOI: 10.1007/s00330-023-10326-7.Peer-Reviewed Original ResearchConventional transarterial chemoembolizationTreatment response assessmentEthiodized oilHepatocellular carcinomaTransarterial chemoembolizationTreatment responseResponse assessmentIntermediate-stage hepatocellular carcinomaDuration of responsePortion of tumorPost-treatment imagingTissue drug concentrationsPost-treatment prognosisChemotherapy solutionLiver transplantationLocoregional therapyChemotherapy dosesCombination therapyStandard treatmentTherapy optionsTumor responseImaging appearancesIntraarterial embolizationTumor necrosisTumor vasculatureCorrection: Consensus report from the 10th global forum for liver magnetic resonance imaging: multidisciplinary team discussion
Taouli B, Ba-Ssalamah A, Chapiro J, Chhatwal J, Fowler K, Kang T, Knobloch G, Koh D, Kudo M, Lee J, Murakami T, Pinato D, Ringe K, Song B, Tabrizian P, Wang J, Yoon J, Zeng M, Zhou J, Vilgrain V. Correction: Consensus report from the 10th global forum for liver magnetic resonance imaging: multidisciplinary team discussion. European Radiology 2023, 34: 724-725. PMID: 37930413, PMCID: PMC10791959, DOI: 10.1007/s00330-023-10342-7.Peer-Reviewed Original ResearchConsensus report from the 10th Global Forum for Liver Magnetic Resonance Imaging: developments in HCC management
Taouli B, Ba-Ssalamah A, Chapiro J, Chhatwal J, Fowler K, Kang T, Knobloch G, Koh D, Kudo M, Lee J, Murakami T, Pinato D, Ringe K, Song B, Tabrizian P, Wang J, Yoon J, Zeng M, Zhou J, Vilgrain V. Consensus report from the 10th Global Forum for Liver Magnetic Resonance Imaging: developments in HCC management. European Radiology 2023, 33: 9152-9166. PMID: 37500964, PMCID: PMC10730664, DOI: 10.1007/s00330-023-09928-y.Peer-Reviewed Original ResearchConceptsGadoxetic acid-enhanced magnetic resonance imagingLiver magnetic resonance imagingMagnetic resonance imagingHCC managementResonance imagingOutcome of HCCScreening/surveillanceLiver cancer screeningPrediction of prognosisWestern guidelinesCancer screeningLiver surgeonsLiver surgeryConsensus statementHCC screeningTreatment responseConsensus reportLiver cancerInterventional radiologistsClinical relevanceClinical practiceGadoxetic acidEmerging DataHCCDiagnosisConsensus report from the 10th global forum for liver magnetic resonance imaging: multidisciplinary team discussion
Taouli B, Ba-Ssalamah A, Chapiro J, Chhatwal J, Fowler K, Kang T, Knobloch G, Koh D, Kudo M, Lee J, Murakami T, Pinato D, Ringe K, Song B, Tabrizian P, Wang J, Yoon J, Zeng M, Zhou J, Vilgrain V. Consensus report from the 10th global forum for liver magnetic resonance imaging: multidisciplinary team discussion. European Radiology 2023, 33: 9167-9181. PMID: 37439935, PMCID: PMC10667403, DOI: 10.1007/s00330-023-09919-z.Peer-Reviewed Original ResearchConceptsLiver magnetic resonance imagingLiver surgeonsMagnetic resonance imagingHCC managementInterventional radiologistsResonance imagingLate-stage HCCMultidisciplinary team discussionMultidisciplinary tumor boardMultidisciplinary team approachHepatocellular carcinoma managementLiver cancer patientsCancer patientsTumor boardConsensus reportClinical relevanceTeam approachMultidisciplinary expertsOncologistsSurgeonsTeam discussionRadiologistsImagingMultidisciplinary facultyManagementPredicting tumor recurrence on baseline MR imaging in patients with early-stage hepatocellular carcinoma using deep machine learning
Kucukkaya A, Zeevi T, Chai N, Raju R, Haider S, Elbanan M, Petukhova-Greenstein A, Lin M, Onofrey J, Nowak M, Cooper K, Thomas E, Santana J, Gebauer B, Mulligan D, Staib L, Batra R, Chapiro J. Predicting tumor recurrence on baseline MR imaging in patients with early-stage hepatocellular carcinoma using deep machine learning. Scientific Reports 2023, 13: 7579. PMID: 37165035, PMCID: PMC10172370, DOI: 10.1038/s41598-023-34439-7.Peer-Reviewed Original ResearchExplainable AI for Prostate MRI: Don't Trust, Verify.
Chapiro J. Explainable AI for Prostate MRI: Don't Trust, Verify. Radiology 2023, 307: e230574. PMID: 37039689, PMCID: PMC10323286, DOI: 10.1148/radiol.230574.Peer-Reviewed Original Research
2022
Experimental VX2 Rabbit Liver Tumor Model in Carbon Tetrachloride–Induced Cirrhosis of the Liver
Santana J, Shewarega A, Nam D, Kahl V, Madoff D, Zhang X, Chapiro J. Experimental VX2 Rabbit Liver Tumor Model in Carbon Tetrachloride–Induced Cirrhosis of the Liver. Journal Of Vascular And Interventional Radiology 2022, 34: 404-408.e1. PMID: 36473611, PMCID: PMC11037556, DOI: 10.1016/j.jvir.2022.11.026.Peer-Reviewed Original ResearchConceptsLiver cirrhosisMale New Zealand white rabbitsRabbit liver tumor modelCirrhotic liver backgroundReproducible tumor growthVX2 liver cancerLeft hepatic lobeNew Zealand white rabbitsDuration of treatmentLiver tumor modelCross-sectional imagingVX2 rabbit liver tumor modelZealand white rabbitsHepatic lobeHistopathological evaluationMajor underlying factorHepatic tumorsIntragastric administrationHepatocellular carcinomaLiver tumorsLiver cancerCirrhosisUnmet needTumor growthVX2 tumorsConventional vs. Drug-Eluting Beads Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma—A Propensity Score Weighted Comparison of Efficacy and Safety
Savic L, Chen E, Nezami N, Murali N, Hamm C, Wang C, Lin M, Schlachter T, Hong K, Georgiades C, Chapiro J, Gaupp F. Conventional vs. Drug-Eluting Beads Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma—A Propensity Score Weighted Comparison of Efficacy and Safety. Cancers 2022, 14: 5847. PMID: 36497329, PMCID: PMC9738175, DOI: 10.3390/cancers14235847.Peer-Reviewed Original ResearchMR Imaging–Based In Vivo Macrophage Imaging to Monitor Immune Response after Radiofrequency Ablation of the Liver
Santana J, Petukhova-Greenstein A, Gross M, Hyder F, Pekurovsky V, Gottwald L, Boustani A, Walsh J, Kucukkaya A, Malpani R, Madoff D, Goldberg S, Ahmed M, Joshi N, Coman D, Chapiro J. MR Imaging–Based In Vivo Macrophage Imaging to Monitor Immune Response after Radiofrequency Ablation of the Liver. Journal Of Vascular And Interventional Radiology 2022, 34: 395-403.e5. PMID: 36423815, PMCID: PMC11042914, DOI: 10.1016/j.jvir.2022.11.013.Peer-Reviewed Original ResearchConceptsImmune responseT1-weighted MRPrussian blue stainingRadiofrequency ablationRF ablationC57BL/6 wild-type miceMR imagingDose-escalation studyLocal immune responseMass cytometryWild-type miceRadiological-pathological correlationBlue stainingT1-weighted MR imagingHepatic radiofrequency ablationCD68 antibodyUntreated lobeVivo doseHepatic RF ablationVivo macrophagesMacrophagesMiceMR imaging scannerCoagulation areaCD68Defining textbook outcome for selective internal radiation therapy of hepatocellular carcinoma: an international expert study
Gregory J, Tselikas L, Allimant C, de Baere T, Bargellini I, Bell J, Bilbao JI, Bouvier A, Chapiro J, Chiesa C, Decaens T, Denys A, Duran R, Edeline J, Garin E, Ghelfi J, Helmberger T, Irani F, Lam M, Lewandowski R, Liu D, Loffroy R, Madoff DC, Mastier C, Salem R, Sangro B, Sze D, Vilgrain V, Vouche M, Guiu B, Ronot M. Defining textbook outcome for selective internal radiation therapy of hepatocellular carcinoma: an international expert study. European Journal Of Nuclear Medicine And Molecular Imaging 2022, 50: 921-928. PMID: 36282299, DOI: 10.1007/s00259-022-06002-5.Peer-Reviewed Original ResearchConceptsSelective internal radiation therapyTextbook outcomeInternal radiation therapyHepatocellular carcinomaRadiation therapyPatient-important outcomesLarge observational studiesNuclear medicine physiciansEntire intervention processRandomized trialsRoutine careResultsA totalObservational studyMultistep interventionMedicine physiciansInterventional radiologistsSenior authorClinical roundsCarcinomaTherapyInterventionOutcomesMachine Learning Models for Prediction of Posttreatment Recurrence in Early-Stage Hepatocellular Carcinoma Using Pretreatment Clinical and MRI Features: A Proof-of-Concept Study.
Iseke S, Zeevi T, Kucukkaya AS, Raju R, Gross M, Haider SP, Petukhova-Greenstein A, Kuhn TN, Lin M, Nowak M, Cooper K, Thomas E, Weber MA, Madoff DC, Staib L, Batra R, Chapiro J. Machine Learning Models for Prediction of Posttreatment Recurrence in Early-Stage Hepatocellular Carcinoma Using Pretreatment Clinical and MRI Features: A Proof-of-Concept Study. American Journal Of Roentgenology 2022, 220: 245-255. PMID: 35975886, PMCID: PMC10015590, DOI: 10.2214/ajr.22.28077.Peer-Reviewed Original ResearchConceptsEarly-stage hepatocellular carcinomaLiver transplantHepatocellular carcinomaImaging featuresPosttreatment recurrenceOrgan allocationMean AUCLiver transplant eligibilityPretreatment clinical characteristicsPretreatment MRI examinationsKaplan-Meier analysisKaplan-Meier curvesClinical characteristicsImaging surveillanceTherapy allocationTransplant eligibilityUnderwent treatmentClinical parametersRetrospective studyUnpredictable complicationMRI dataConcept studyPoor survivalClinical impactPretreatment MRIAnalysis of Tumor Burden as a Biomarker for Patient Survival with Neuroendocrine Tumor Liver Metastases Undergoing Intra-Arterial Therapies: A Single-Center Retrospective Analysis
Miszczuk M, Chapiro J, Do Minh D, van Breugel JMM, Smolka S, Rexha I, Tegel B, Lin M, Savic LJ, Hong K, Georgiades C, Nezami N. Analysis of Tumor Burden as a Biomarker for Patient Survival with Neuroendocrine Tumor Liver Metastases Undergoing Intra-Arterial Therapies: A Single-Center Retrospective Analysis. CardioVascular And Interventional Radiology 2022, 45: 1494-1502. PMID: 35941241, PMCID: PMC9587516, DOI: 10.1007/s00270-022-03209-9.Peer-Reviewed Original ResearchConceptsNeuroendocrine tumor liver metastasesMedian overall survivalIntra-arterial therapyLow tumor burdenTumor burdenOverall survivalLiver metastasesPrognostic factorsTumor diameterTB groupLonger median overall survivalRetrospective single-center analysisSingle-center retrospective analysisHigh TB groupLow TB groupRespective hazard ratiosHigh tumor burdenSingle-center analysisIndependent prognostic factorStrong prognostic factorDrug-eluting beadsLargest liver lesionPrediction of survivalHazard ratioPatient survival